BiotechTube

Ibrutinib 420 mg + Ibrutinib 560 mg

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Leukemia, Lymphocytic, Chronic, B-Cell

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Trial Timeline

Jun 26, 2019 → May 3, 2023

NCT ID
NCT03190330

About Ibrutinib 420 mg + Ibrutinib 560 mg

Ibrutinib 420 mg + Ibrutinib 560 mg is a approved stage product being developed by Johnson & Johnson for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03190330. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03190330ApprovedCompleted

Competing Products

20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
Pirtobrutinib + IbrutinibEli LillyPhase 3
77
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85